Skip to main content

Table 1 Regression analysis for the outcomes

From: Association between tocilizumab and emerging multidrug-resistant organisms in critically ill patients with COVID-19: A multicenter, retrospective cohort study

Outcomes

Crude analysis

p-value^^

Odds ratio (OR) (95%CI)

p-value for adjusted analysis$**

Control group

Tocilizumab group

Secondary infection (Bacterial/fungal), n (%)

214/476 (44.9)

132/261 (50.5)

0.14

1.34 (0.91, 1.94)

0.13

Resistant organisms (i.e. MDR, EDR, PDR), n (%)

82/141(58.1)

54/84 (64.2)

0.36

1.00 (0.51, 1.98)

0.99

CRE detection, n (%)

21/476 (4.4)

10/262 (3.8)

0.69

0.67 (0.29, 1.54)

0.34

  1. ^^Chi-square test is used to calculate the p-value
  2. $**Multivariable Logistic regression is used after adjusting for patient’s comorbidities (i.e. DM, CKD on dialysis), history of hospitalization or invasive procedure (Surgery) within 1 year, history of antibiotics exposure in the last 3 months, systemic corticosteroids during ICU and ICU LOS to calculate odds ratio and p-value